Affected skin examination in psoriatic patients in the courseof Infliximab therapy (a morphologic analysis)
- Authors: Katunina OR1, Znamenskaya LF1, Matushevskaya Y.I1, Katunina OR1, Znamenskaya LF1, Matushevskaya Y.I1
-
Affiliations:
- Issue: Vol 87, No 3 (2011)
- Pages: 58-62
- Section: Articles
- Submitted: 11.03.2020
- Published: 15.06.2011
- URL: https://vestnikdv.ru/jour/article/view/1019
- DOI: https://doi.org/10.25208/vdv1019
- ID: 1019
Cite item
Full Text
Abstract
pathomorphologic picture of affected skin in psoriatic patients in the course of therapy.
Keywords
About the authors
O R Katunina
Email: katunina@cnikvi.ru
L F Znamenskaya
Yu I Matushevskaya
O R Katunina
L F Znamenskaya
Yu I Matushevskaya
References
- Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin. Dermatol. 2007; 25: 6: 535-546.
- Krueger J.G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann. Rheum. Dis. 2005; 64: 1130-1136.
- Griffits C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370: 263-271.
- Lowes M.A., Kikuchi T., Fuentes-Duculan J. et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. of Invest. Dermatol. 2008; 128: 1207-1211.
- Braun J., Sieper J. Owerview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert. Opin. Biol. Ther. 2003; 3: 1: 141-168.
- Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J.Am. Acad. Dermatol. 2004; 51: 4: 534-542.
- Кубанов А.А., Матушевская Ю.И. Опыт применения препарата инфликсимаб в лече- нии больных псориазом тяжелого течения. Вестн. дерматол. и венерол. 2008; 6: 81-86.
- Курдина М.И., Макаренко Л.А., Полянская А.А. Клинико-иммунологические параллели у больных псориазом на фоне лечения ин- фликсимабом. Клин. дерматол. и венерол. 2010; 2: 77-80.